A woman sits in an antenatal clinic in Nairobi, clutching a prescription bottle as if it were a fragile secret. For her, the pills are a vital tether to stability for her developing fetus, she has been told, they are a source of profound, gnawing uncertainty. This scene repeats in clinics across the world, where the decision to continue or cease antidepressant medication during pregnancy remains one of the most agonizing clinical dilemmas facing expectant mothers.

The prevailing narrative has long been one of caution, often leading women to abruptly stop their treatment the moment they see a positive test result. However, medical consensus is shifting. New research suggests that the risks of untreated maternal mental illness—ranging from severe depression to suicide and postpartum psychosis—often far outweigh the rare complications associated with the use of selective serotonin reuptake inhibitors, commonly known as SSRIs.

The Weight of the Decision

For a pregnant woman living with depression, the pressure to choose between her own mental stability and the perceived safety of her unborn child creates a unique psychological burden. According to data published in early 2026, roughly 10% to 20% of pregnant women globally experience some form of mental disorder, with depression being the most prevalent. In developing nations, including Kenya, these figures can climb higher due to complex social determinants, including poverty, food insecurity, and a lack of community support structures.

When a patient discontinues medication, the risk of relapse is acute. Studies presented at the 2026 Society for Maternal-Fetal Medicine meeting revealed that pregnant patients who stopped taking their antidepressants were almost twice as likely to experience a mental health emergency—such as suicidal ideation, psychosis, or substance overdose—compared to those who continued their prescribed therapy. The peaks for these emergencies often occur during the first and ninth months of pregnancy, the very times when maternal stress levels are traditionally at their highest.

The Clinical Reality of Risks

The fear of SSRIs is often rooted in earlier studies that suggested links to rare conditions like persistent pulmonary hypertension of the newborn or certain cardiac malformations. Yet, large-scale, modern cohort studies have consistently found these risks to be statistically minimal. The alternative—untreated depression—carries a well-documented trajectory of adverse health outcomes that can be more detrimental to the child and the mother.

• Increased risk of preterm birth: Untreated depression is a major driver of early delivery, which impacts neonatal lung development.
• Low birth weight: Physiological stress from maternal depression can restrict intrauterine growth.
• Preeclampsia: A potentially life-threatening condition associated with high blood pressure, which occurs more frequently in depressed, untreated pregnant individuals.
• Attachment challenges: Maternal mental health issues are a strong predictor of postpartum depression, which hinders bonding, breastfeeding, and the overall capacity for caregiving in the critical first year.

Healthcare providers, including those guided by the Ministry of Health’s recent initiatives in Kenya, are increasingly trained to view maternal mental health as a component of holistic pregnancy care. The objective is to move away from stigmatization and towards an individualized risk-benefit analysis. A woman with a history of severe depressive episodes requires a different treatment plan than one with mild, situational anxiety.

Navigating the Kenyan Context

In Kenya, the path to care is fraught with institutional barriers. While the government launched the National Clinical Guidelines for the Management of Common Mental Disorders in 2024 to better integrate mental health into primary care, the treatment gap remains significant. Many public clinics still struggle to provide consistent psychiatric follow-up for pregnant women. Consequently, women often lack the professional guidance needed to make an informed choice, relying instead on anecdotal advice or fear-based social media narratives.

Dr. Josephine Mwangi, a consultant psychiatrist at a leading Nairobi referral hospital, emphasizes that a conversation about medication is not a conversation about a binary choice. It is about continuity. Women are encouraged to consult with obstetricians and psychiatrists to evaluate their current dosage, explore safer alternatives if necessary, and establish a postpartum plan. The goal is to avoid the "stop-start" cycle, which often destabilizes the patient more than a consistent, low-dose regimen might.

The Future of Maternal Care

The imperative now is to replace the culture of fear with a culture of supported clinical decision-making. Pregnant women deserve to know that taking care of their mind is an essential part of taking care of their child. The data is clear: the healthiest outcome for the baby is a mother who is stable, present, and capable of caring for herself. Ignoring maternal depression under the guise of "natural" pregnancy is no longer considered a responsible medical stance.

As research continues to refine the understanding of neurodevelopmental outcomes, the medical field must maintain a focus on the tangible, immediate dangers of untreated illness. For the expectant mother in the Nairobi clinic, or anywhere else in the world, the right decision is rarely found in isolation. It is found in a partnership between the patient and the provider—one that validates her symptoms, acknowledges her fears, and prioritizes the long-term well-being of both mother and child.